AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$UNCY

Unicycive Therapeutics, Inc.

Price · $UNCYvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $UNCY in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $UNCY in the last 30 days.

Top stories · $UNCYMore →
MAR 25·ACCESS NewswireMed

Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of investors who purchased securities before March 29, 2024. The investigation seeks to determine if Unicycive and its officers engaged in corporate wrongdoing. Shareholders are encouraged to contact the firm for more information and to assist with the investigation.

MAR 12·GlobeNewswire

Important Notice to Long-Term Shareholders of Integer

Grabar Law Office is investigating potential breaches of fiduciary duties by officers and directors of Integer Holdings Corp. (NYSE: ITGR), Molina Healthcare, Inc. (NYSE: MOH), Unicycive Therapeutics, Inc. (NASDAQ: UNCY), and WEBTOON Entertainment Inc. (NASDAQ: WBTN). Shareholders who held shares of these companies before specific dates are encouraged to contact the law office to explore options for corporate reforms and the return of funds. The investigations cite alleged misleading statements and failures to disclose material adverse facts to investors.

MAR 10·GlobeNewswire

Important Notice to Long-Term Shareholders of Boston Scientific Corporation (NYSE: BSX): Corcept Therapeutics, Inc. (NASDAQ: CORT); Nektar Therapeutics (NASDAQ: NKTR): and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf

Grabar Law Office is investigating claims on behalf of long-term shareholders of Boston Scientific, Corcept Therapeutics, Nektar Therapeutics, and Unicycive Therapeutics regarding alleged breaches of fiduciary duty by officers and directors. The investigations stem from recent federal securities fraud class action lawsuits or emerging disclosures about company performance and regulatory issues. Shareholders who purchased shares before specific dates are encouraged to contact the law office to potentially seek corporate reforms and other remedies at no cost.

News on $UNCY

All news →